Cosentyx has posted solid, if unspectacular, sales growth in recent times but Novartis AG's flagship immunology product has made a stellar return, helped in no small part by its recent approval for hidradenitis suppurativa (HS).
The performance of Cosentyx (secukinumab) was one of the highlights of Novartis's second quarter results (see table below). Harry Kirsch, the company’s chief financial officer, commented to Scrip that "we are now at over a $6bn run rate for the year and, as you know, the last couple of years were nearer $5bn, a bit flatter